Literature DB >> 1721486

New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope.

T J O'Brien1, L M Raymond, G A Bannon, D H Ford, H Hardardottir, F C Miller, J G Quirk.   

Abstract

CA 125 is an antigenic determinant located on the surface of ovarian carcinoma cells and elevated in the serum of greater than 90% of patients with carcinoma. The antigen, derived from the ovarian epithelium, has been described as a mucinlike glycoprotein greater than 200 kd. To date little is known of the metabolic regulation or expression of this antigen in either normal or neoplastic tissues. New monoclonal antibodies that we describe here recognize both unique and similar epitopes to OC 125. These reagents may allow for a more complete definition of the structure and expression of the CA 125 complex. These antibodies recognize high-molecular weight (greater than 200 kd) subspecies and a lower-molecular-weight (68 kd) subspecies of the antigen and identify it in the cytoplasm and the extracellular matrix of CA 125-producing cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1721486     DOI: 10.1016/0002-9378(91)90046-t

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  10 in total

Review 1.  Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.

Authors:  Maria Koutsaki; Apostolos Zaravinos; Demetrios A Spandidos
Journal:  Pathol Oncol Res       Date:  2011-12-09       Impact factor: 3.201

Review 2.  Peripheral biomarkers of endometriosis: a systematic review.

Authors:  K E May; S A Conduit-Hulbert; J Villar; S Kirtley; S H Kennedy; C M Becker
Journal:  Hum Reprod Update       Date:  2010-05-12       Impact factor: 15.610

3.  Early detection of ovarian cancer.

Authors:  Partha M Das; Robert C Bast
Journal:  Biomark Med       Date:  2008-06       Impact factor: 2.851

4.  An antibody-lectin sandwich assay for the determination of CA125 antigen in ovarian cancer patients.

Authors:  R Madiyalakan; M Kuzma; A A Noujaim; M R Suresh
Journal:  Glycoconj J       Date:  1996-08       Impact factor: 2.916

5.  Development and characterization of three novel monoclonal antibodies against CA-125.

Authors:  Tatiana Michurina; Maxim Kerzhner; Boris Klimovich
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-10

6.  Reflection on the discovery of carcinoembryonic antigen, prostate-specific antigen, and cancer antigens CA125 and CA19-9.

Authors:  Eleftherios P Diamandis; Robert C Bast; Phil Gold; T Ming Chu; John L Magnani
Journal:  Clin Chem       Date:  2012-11-30       Impact factor: 8.327

7.  False changes in CA 125 levels in ovarian cancer patients after infusion of OC125 fragments for diagnostic and therapeutic purpose.

Authors:  J Reinsberg; U Wagner; D Krebs
Journal:  Arch Gynecol Obstet       Date:  1994       Impact factor: 2.344

8.  Tumour markers: An overview.

Authors:  T Malati
Journal:  Indian J Clin Biochem       Date:  2007-09

9.  Generation and characterization of a monoclonal antibody to the cytoplasmic tail of MUC16.

Authors:  Ilene K Gipson; Ulla Mandel; Balaraj Menon; Sandra Michaud; Ann Tisdale; Diana Campos; Henrik Clausen
Journal:  Glycobiology       Date:  2017-10-01       Impact factor: 4.313

Review 10.  MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress.

Authors:  Mildred Felder; Arvinder Kapur; Jesus Gonzalez-Bosquet; Sachi Horibata; Joseph Heintz; Ralph Albrecht; Lucas Fass; Justanjyot Kaur; Kevin Hu; Hadi Shojaei; Rebecca J Whelan; Manish S Patankar
Journal:  Mol Cancer       Date:  2014-05-29       Impact factor: 27.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.